KDR and neoplasm: Overall, TU2218 is a dual inhibitor that simultaneously inhibits ALK5 and VEGFR2 and is expected to create a favorable environment for immune checkpoint inhibitors to act by controlling various immunosuppressive factors in the tumor microenvironment.